Anna Estefanell-Tejero

  • Citations Per Year
Learn More
WHAT IS KNOWN AND OBJECTIVE It is now estimated that about 5% of cetuximab-treated patients and about 3% of panitumumab-treated patients will develop grade 3-4 hypomagnesemia. The aim of this study(More)
  • 1